FGEN (FibroGen Inc) Net Profit

Corporate emblem and logo of fibrogen.com (FGEN)

FibroGen, Inc. (FGEN) adheres to basic biosafety and waste disposal standards. However, a severe liquidity shortage and past test failures create a bankruptcy threat. The company's net income demonstrates current financial stability, with the latest value recorded as 0.17. This complements a strategy of expanding its small-molecule portfolio by licensing formulas to industry behemoths to capture market share.

FGEN (FibroGen) Company Net Income history from 07/04/2022 to 01/08/2026

Financial and market metric breakdowns for FibroGen (FGEN)

- price and consensus price forecast:
Stock Quotes FibroGen Corporation|FGEN - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization FibroGen Corporation|FGEN - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share FibroGen|FGEN - Company Book Value|Market-to-Book Ratio fibrogen.com|FGEN - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital FibroGen, Inc.|FGEN - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital FibroGen Inc|FGEN - Company Aggregate Debts|Debts to Book Value FibroGen Corporation|FGEN - Company Long-Term Debt|Company Short-Term Loans and Borrowings FibroGen|Critical Liquidity Ratio fibrogen.com
- net income and valuation multiples indicators:
FGEN - Net Profit
Fundamental valuation:FGEN FibroGen Corporation
Flagship merchandise of FibroGen Inc

Portfolio managers evaluate the operating model of FibroGen, Inc. (FGEN) through the lens of real cash flow, where this indicator captures the daily difference between revenues and expenses, separating actual profit from market expectations. An analysis of the company's aggregate financial result allows for an assessment of the commercialization efficiency of the oral drug in the nephrology segment, confirming the resilience of the business model during the transition from injections to tablet forms.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Net Profit TBPH (Theravance Biopharma, Inc.)|AQST (Aquestive Therapeutics Inc) - Profit After Tax|scPharma - Net Profit|Net Financial Result Tectonic Therapeutic, Inc. TECX|TNXP: Net Profit|SXTC (China SXT Pharmaceuticals, Inc.) - Company Net Income|Company Net Income Eupraxia Pharmaceuticals, Inc.|BHST: Final Profit|Company Net Income Invizyne Technologies, Inc. (EXOZ)|ORMP - Company Net Income|Net Profit ENTX (Entera Bio)|Annual Net Income ipatherapeutics.com|ABVC BioPharma, Inc. - Net Profit|Company Net Income Cumberland Pharmaceuticals Inc|Quantum BioPharma Limited (QNTM) - Company Net Income|Company Profit TELO|Net Income RANI|SNYR: Final Profit|Net Profit RLYB|Net Financial Result lexariabioscience.com|Company Net Income Pulmatrix Corp PULM|PTHL: Company Profit|Aptorum - Net Profit|lyratherapeutics.com (LYRA) - Net Income|IBO (Impact BioMedical Inc) - Net Income|TNFA - Net Financial Result|YCBD (cbdMD Inc.) - Net Profit|PainReform Corp - Profit After Tax|Net Profit CYTO|lipella.com (LIPO) - Annual Net Income|Net Profit OPTN (OptiNose)|Pieris Pharmaceuticals Inc (PIRS) - Company Net Income|PROC - Company Net Income|PTPI (Petros Pharma) - Company Profit|Qilian International (QLI) - Company Net Income|Profit After Tax SLRN (acelyrin.com)|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit